<DOC>
	<DOC>NCT00957944</DOC>
	<brief_summary>The major aim of this study is to investigate and compare the drug amount delivered to the body after sequential application of 2 rotigotine transdermal patches from 2 different manufacturing sites.</brief_summary>
	<brief_title>Study in Healthy Volunteers to Prove That Two Rotigotine Patches From Different Manufacturing Sites Deliver Equivalent Drug Amount to the Body</brief_title>
	<detailed_description />
	<mesh_term>N 0437</mesh_term>
	<criteria>healthy, white, male volunteers between 18 and 55 years of age (inclusive) BMI between 19 and 28 kg/m² (inclusive) previous participation in a clinical study with Rotigotine history or current condition of epilepsy and/or seizures known clinically relevant allergy or known/suspected clinically relevant drug hypersensitivity history of significant skin hypersensitivity to adhesives or other transdermal products or recently unresolved contact dermatitis history or present condition of an atopic or eczematous dermatitis, psoriasis, and/or an active skin disease clinically relevant abnormality in physical examination, ECG, vital signs or safety laboratory examinations positive HIV, hepatitis B or C test or positive alcohol or drug test relevant hepatic or renal dysfunction intake of medication that might interfere with the test drug within 2 weeks prior to dosing thickly haircovered abdomen resulting in difficulties in finding appropriate patch application sites</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro®</keyword>
</DOC>